An open-label randomized active-controlled phase II clinical study to assess the efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer (PROFECTA-II/GOG-3044)
- 10 April 2025
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 194, 145-152
Abstract
No abstract availableKeywords
Funding Information
- GOG Foundation
This publication has 23 references indexed in Scilit:
- Treatment-related adverse events in patients with advanced breast cancer receiving adjuvant AKT inhibitors: a meta-analysis of randomized controlled trialsEuropean Journal of Clinical Pharmacology, 2024
- Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian CancerNew England Journal of Medicine, 2023
- Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous CarcinomaJAMA Oncology, 2023
- Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancerGynecologic Oncology, 2022
- Targeting PI3K/Akt signal transduction for cancer therapySignal Transduction and Targeted Therapy, 2021
- Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancernpj Breast Cancer, 2021
- A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumorsInvestigational New Drugs, 2018
- Moving beyond the platinum sensitive/resistant paradigm for patients with recurrent ovarian cancerGynecologic Oncology, 2016
- Targeting PI3K signalling in cancer: opportunities, challenges and limitationsNature Reviews Cancer, 2009
- Perturbations of the AKT signaling pathway in human cancerOncogene, 2005